Topical Safety Study of Topical Diltiazem Hydrochloride

NCT01816529 | Unknown Phase 1

• 1 other identifier: VEN307-DERM-001
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions.

Conditions

Diltiazem Skin Sensitivity.

Outcome Measures

Primary Outcomes (1)

• Determine the potential of Diltiazem Hydrochloride 2% Cream to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions.

  A total cumulative irritation score for each subject and product will be calculated by summing each individual's scores on each of the 9 evaluation days in the Induction Phase. Cumulative irritancy during Induction will be quantified by means of the cumulative irritancy index (CII), defined as the mean of irritation scores received during the Induction Phase (9 readings). The determination of dermal sensitization potential will be based on specific scoring criteria derived from observations in the Challenge Phase of the study and confirmed in the Rechallenge Phase, if necessary. The recurrence of a cutaneous response at Rechallenge equivalent to or more severe than that observed at challenge will be considered indicative of a sensitization reaction. The observation of such a response in even a single subject suggests that the test product may have the potential to cause hypersensitivity.

  6 weeks after the first topical application

Study Arms (4)

Topical Diltiazem Hydrochloride 2% Cream

EXPERIMENTAL

0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Drug: Diltiazem Hydrochloride 2% Cream

Vehicle Cream

PLACEBO COMPARATOR

0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Drug: Vehicle Cream

0.1% solution of sodium lauryl sulfate (SLS)

ACTIVE COMPARATOR

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Drug: 0.1% solution of sodium lauryl sulfate (SLS)

0.9% Saline

PLACEBO COMPARATOR

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Drug: Saline (0.9%)

Interventions

Diltiazem Hydrochloride 2% Cream DRUG

0.2 g applied topically to the infrascapular area of the back.

Topical Diltiazem Hydrochloride 2% Cream

Vehicle Cream DRUG

Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.

Vehicle Cream

0.1% solution of sodium lauryl sulfate (SLS) DRUG

0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.

0.1% solution of sodium lauryl sulfate (SLS)

Saline (0.9%) DRUG

0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.

0.9% Saline

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Are healthy males or females (to be confirmed by medical history);
• Are 18 years of age or older;
• In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
• In the case of females of childbearing potential: have a negative urine pregnancy test (UPT) at Screening, and are willing to submit to a pregnancy test at the end of study (EOS);
• Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
• Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
• Read, understand, and provide signed informed consent.

You may not qualify if:

• Have sick sinus syndrome except in the presence of a functioning ventricular pacemaker (confirmed via medical history);
• Have second-or third-degree AV block except in the presence of a functioning ventricular pacemaker (confirmed via medical history);
• Have hypotension (less than 90 mm Hg systolic, determined by performing vital signs);
• Have acute myocardial infarction and pulmonary congestion documented by x-ray (confirmed via medical history);
• Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
• Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
• Are using systemic/topical corticosteroids for 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
• Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
• Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
• Have psoriasis and/or active atopic dermatitis/eczema;
• Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
• Have a known sensitivity to constituents present in the material being evaluated;
• Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
• Have received treatment for any type of internal cancer within 5 years prior to study entry;
• Have a history of, or are currently being treated for skin cancer;

Sponsors & Collaborators

• Ventrus Biosciences, Inc: lead

Study Sites (1)

TKL Research

Paramus, New Jersey, 07652, United States

Location

MeSH Terms

Interventions

Diltiazem; Sodium Chloride

Intervention Hierarchy (Ancestors)

Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2013
• First Posted: March 22, 2013
• Study Start: March 1, 2013
• Primary Completion: June 1, 2013
• Study Completion: September 1, 2013
• Last Updated: August 21, 2013

Record last verified: 2013-07

Locations

US (1)